Kuros Biosciences, 1735 Founders Pkwy Suite 300, Alpharetta, GA (2026)

06/03/2026

𝗡𝗼𝘁 𝗮𝗹𝗹 𝘀𝘂𝗿𝗳𝗮𝗰𝗲𝘀 𝗮𝗿𝗲 𝗰𝗿𝗲𝗮𝘁𝗲𝗱 𝗲𝗾𝘂𝗮𝗹.

See the MagnetOs™ NeedleGrip™ surface technology under a real scanning electron microscope at 20,000x magnification.

Watch the full video on our YouTube channel: https://hubs.ly/Q04jz9mn0

06/01/2026

𝗪𝗲𝗹𝗰𝗼𝗺𝗲 𝘁𝗼 𝗞𝘂𝗿𝗼𝘀, 𝗜.𝗩. 𝗛𝗮𝗹𝗹!

Today, we’re excited to officially welcome I.V. Hall as Chief Operating Officer of Kuros Biosciences.

I.V. brings more than 30 years of medical device leadership experience, with deep expertise across R&D, product development, commercialization, and strategic operations. He's widely respected in the orthopedic trauma and extremities space – exactly where Kuros is accelerating.

Known for building high-performing teams and translating science into surgical solutions patients can count on, I.V. joins Kuros at an exciting time as we continue to strengthen our operational infrastructure and advance our innovation pipeline.

Effective today, I.V. will succeed Sjoerd Musters, who will conclude his role as the current Chief Operating Officer. By mutual agreement, Sjoerd will remain with the Company through August 1, 2026, to ensure a smooth transition of responsibilities.

Chris Fair, Chief Executive Officer of Kuros Biosciences, said: “We sincerely thank Sjoerd Musters for his pivotal role in building and strengthening Kuros’ operational foundation during this period of rapid growth. On behalf of the entire company, I appreciate his outstanding service and wish him continued success in his future endeavors.”

… And yes, I.V. really does go by I.V., short for Harry Thomas Hall, IV, a name with a built-in leadership title.

Please join us in giving I.V. a warm welcome to Kuros!

05/29/2026

𝗜𝗖𝗬𝗠𝗜 – 𝗪𝗲𝗯𝗶𝗻𝗮𝗿 𝗿𝗲𝗰𝗼𝗿𝗱𝗶𝗻𝗴 𝗻𝗼𝘄 𝗮𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲!

In partnership with BroadWater, LLC, watch top spine surgeons Dr. Alpesh A Patel MD MBA FACS, Dr. Todd Allen, and Dr. Faheem Sandhu host a bold, evidence-based biologics webinar titled: “𝐼𝑠 𝑖𝑡 𝑎𝑐𝑡𝑢𝑎𝑙𝑙𝑦 𝑓𝑢𝑠𝑒𝑑? 𝐴 𝑠𝑢𝑟𝑔𝑒𝑜𝑛-𝑙𝑒𝑑 𝑐𝑜𝑛𝑣𝑒𝑟𝑠𝑎𝑡𝑖𝑜𝑛 𝑜𝑛 𝑖𝑛𝑡𝑒𝑟𝑝𝑟𝑒𝑡𝑖𝑛𝑔 𝑓𝑢𝑠𝑖𝑜𝑛 𝑖𝑚𝑎𝑔𝑖𝑛𝑔.”

This fireside chat style discussion moved beyond traditional lectures to tackle a question many clinicians face in practice: how can we be confident that what we see on imaging is truly bone?

▶𝗪𝗮𝘁𝗰𝗵 𝘁𝗵𝗲 𝗽𝗮𝗻𝗲𝗹 𝗱𝗶𝘀𝗰𝘂𝘀𝘀𝗶𝗼𝗻 𝘁𝗼 𝗵𝗲𝗮𝗿 𝗵𝗼𝘄 𝗹𝗲𝗮𝗱𝗶𝗻𝗴 𝘀𝘂𝗿𝗴𝗲𝗼𝗻𝘀 𝗶𝗻𝘁𝗲𝗿𝗽𝗿𝗲𝘁 𝗳𝘂𝘀𝗶𝗼𝗻 𝘀𝘂𝗰𝗰𝗲𝘀𝘀: https://hubs.ly/Q04jnmCK0

05/27/2026

MagnetOs™ is changing how surgeons approach bone healing – and we'll show you how during the 𝗞𝘂𝗿𝗼𝘀 𝗕𝗶𝗼𝘀𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗖𝗮𝗽𝗶𝘁𝗮𝗹 𝗠𝗮𝗿𝗸𝗲𝘁𝘀 𝗗𝗮𝘆 on June 17, 2026.

Join us live in Zürich or virtually via webcast, as our executive leadership team shares Kuros' global commercial strategy, growth vision, and business transformation initiatives.

We're honored to welcome special guest Mr. Andy Goldberg OBE MD MBBS FRCS, orthopedic surgeon at The Wellington Hospital, UK, who will share his clinical experience with MagnetOs in foot & ankle procedures – including a patient perspective on real-world outcomes.

𝗪𝗵𝗮𝘁 𝘁𝗼 𝗲𝘅𝗽𝗲𝗰𝘁:
Expanding our global commercial strategy
Differentiating through evidence generation
Surgeon and patient perspectives on MagnetOs in extremities
Scaling the business to drive long-term quality growth and value

𝗗𝗮𝘁𝗲 / 𝗧𝗶𝗺𝗲 / 𝗟𝗼𝗰𝗮𝘁𝗶𝗼𝗻:
Wednesday, 17 June 2026
9am-1pm CET (3am-7am ET)
Mandarin Oriental Savoy, Zürich – or join virtually

𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝘁𝗼 𝗮𝘁𝘁𝗲𝗻𝗱:
In-person RSVP link: https://hubs.ly/Q04hZQKY0
Live webcast link: https://hubs.ly/Q04hZMlF0

05/21/2026

𝗪𝗵𝗲𝗿𝗲 𝘁𝗵𝗲𝗿𝗲’𝘀 𝘀𝗺𝗼𝗸𝗲… 𝘁𝗵𝗲𝗿𝗲’𝘀 𝗳𝘂𝘀𝗶𝗼𝗻

In a Level I human clinical study published in 𝑆𝑝𝑖𝑛𝑒, nearly 1 in 5 patients were active smokers – an important detail given the challenge of fusing this high-risk patient population.*¹⁻³

In this group, the difference in outcomes was even more dramatic than in the full study population: 𝟳𝟰% 𝘃𝘀. 𝟯𝟬% 𝗳𝘂𝘀𝗶𝗼𝗻 𝗼𝗳 𝗠𝗮𝗴𝗻𝗲𝘁𝗢𝘀 𝘃𝘀. 𝗮𝘂𝘁𝗼𝗴𝗿𝗮𝗳𝘁 𝗶𝗻 𝗮𝗰𝘁𝗶𝘃𝗲 𝘀𝗺𝗼𝗸𝗲𝗿𝘀, 𝗰𝗼𝗺𝗽𝗮𝗿𝗲𝗱 𝘁𝗼 𝟳𝟵% 𝘃𝘀. 𝟰𝟳% 𝗼𝘃𝗲𝗿𝗮𝗹𝗹.*¹˒²

*19 of initial 100 patients were active smokers. Radiographic fusion data of the smoker subgroup were not statistically analyzed as a subgroup and were not included in the peer-reviewed publication of the study.¹
1. Stempels, et al. 𝑆𝑝𝑖𝑛𝑒. 2024;49(19):1323-1331.
2. Van Dijk, LA. 24th SGS Annual Meeting (Swiss Society of Spinal Surgery). Basel, Switzerland. Aug 2024.
3. Berman, et al. 𝐼𝑛𝑡 𝐽 𝑆𝑝𝑖𝑛𝑒 𝑆𝑢𝑟𝑔. 2017;11(4):29.

05/19/2026

𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝘀𝘂𝗽𝗽𝗼𝗿𝘁𝗶𝗻𝗴 𝘁𝗵𝗲 𝘂𝘀𝗲 𝗼𝗳 𝗯𝗶𝗼𝗮𝗰𝘁𝗶𝘃𝗲 𝗴𝗹𝗮𝘀𝘀 𝗶𝗻 𝗣𝗟𝗙 𝗿𝗲𝗺𝗮𝗶𝗻𝘀 𝗹𝗶𝗺𝗶𝘁𝗲𝗱.

A recent systematic review concluded that high quality data supporting the use of bioactive glasses in cervical and lumbar spinal fusion is lacking. Especially for posterolateral fusions (PLF), excessive resorption, limited efficacy as standalone grafts, and low fusion rates were found.

Additionally, the authors concluded that most studies investigating bioactive glasses for PLF had a moderate to high potential for bias.¹

The data from a prospective, multi-center, RCT indicated the superiority of MagnetOs™ versus autograft (≥50% iliac crest) for posterolateral spinal fusions. At 1 year follow-up 𝗠𝗮𝗴𝗻𝗲𝘁𝗢𝘀 𝗵𝗮𝗱 𝗮 𝗳𝘂𝘀𝗶𝗼𝗻 𝗿𝗮𝘁𝗲 𝗼𝗳 𝟳𝟵%, while autograft had a fusion rate of only 47%.*²

*Please refer to the Instructions for Use for a full list of indications, contraindications, precautions, and warnings.
1. Liu, et al. 𝐽 𝑆𝑝𝑖𝑛𝑒 𝑆𝑢𝑟𝑔 2026;12(1):10
2. Stempels, et al. 𝑆𝑝𝑖𝑛𝑒. 2024;49(19):1323-1331.

05/14/2026

𝗣𝗿𝗼𝗽𝗮𝗴𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗮𝗰𝘁𝗶𝗼𝗻: MagnetOs™ turns implant volume into bone.

Quite simply, 𝘆𝗼𝘂 𝗴𝗲𝘁 𝗼𝘂𝘁 𝘄𝗵𝗮𝘁 𝘆𝗼𝘂 𝗽𝘂𝘁 𝗶𝗻 𝘄𝗶𝘁𝗵 𝘁𝗵𝗶𝘀 𝗯𝗼𝗻𝗲 𝗴𝗿𝗮𝗳𝘁.*¹

To learn more about how MagnetOs compares to other commercially available bone grafts on the market, 𝗰𝗹𝗶𝗰𝗸 𝗵𝗲𝗿𝗲: https://hubs.ly/Q04grj_l0

05/12/2026

𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗴𝘂𝗶𝗱𝗲𝘀 𝗯𝗼𝗻𝗲 𝗴𝗿𝗮𝗳𝘁 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝗼𝗻.

A recent survey study found that surgeons performing pediatric posterior spinal fusion surgeries mostly cited “clinical evidence” and “favorable side effect profile” as factors influencing their current bone graft selection.

Nearly half of the surgeons (𝟰𝟮%) acknowledged that other options, such as iliac crest autograft or BMPS, would have better efficacy than their current choice, but they avoided these grafts due to their higher costs and perceived associated risks.¹

The data of a prospective, multi-center, RCT study indicated the superiority of MagnetOs™ to iliac crest autograft for posterolateral fusions in an adult population. At 1 year follow-up MagnetOs had a 𝗳𝘂𝘀𝗶𝗼𝗻 𝗿𝗮𝘁𝗲 𝗼𝗳 𝟳𝟵%, while autograft had a fusion rate of only 47%.*²

Additionally, MagnetOs contains no human tissue or growth factors which alleviates concerns of disease transmission – making it a safe, proven alternative to autograft.²⁻⁷

*Please refer to the Instructions for Use for a full list of indications, contraindications, precautions, and warnings.

1. Okonkwo, et al. 𝐽 𝑃𝑒𝑑𝑖𝑎𝑡𝑟 𝑆𝑜𝑐 𝑁𝑜𝑟𝑡ℎ 𝐴𝑚. 2025;14:100290
2. Stempels, et al. 𝑆𝑝𝑖𝑛𝑒. 2024;49(19):1323-1331.
3. Instructions for Use MagnetOs Granules
4. Instructions for Use MagnetOs Putty
5. Instructions for Use MagnetOs Easypack Putty†
6. Instructions for Use MagnetOs Flex Matrix†
7. Instructions for Use MagnetOs MIS†
†MagnetOs Easypack Putty, MagnetOs Flex Matrix, MagnetOs MIS are FDA-cleared and are not commercially available outside of the US.

05/08/2026

𝗣𝗿𝗼𝗼𝗳 𝗶𝗻 𝗲𝘃𝗲𝗿𝘆 𝗶𝗺𝗮𝗴𝗲.

There was high engagement from start to finish in Carmel, IN for the CSRS Emerging Leaders podium session.

Dr. Daniel Robinson presented “𝑺𝒆𝒆𝒊𝒏𝒈 𝒊𝒔 𝒃𝒆𝒍𝒊𝒆𝒗𝒊𝒏𝒈”, sharing radiographic and histological perspectives in spine surgery using MagnetOsᵀᴹ.

𝗪𝗮𝗻𝘁 𝘁𝗼 𝗱𝗶𝗴 𝗶𝗻𝘁𝗼 𝘁𝗵𝗲 𝗱𝗮𝘁𝗮? Explore the evidence in our Evidence Hub at the link in our bio.

05/07/2026

We are pleased to announce the appointment of I.V. Hall as Chief Operating Officer effective June 1, 2026. I.V. will succeed Sjoerd Musters, who will conclude his role as the current Chief Operating Officer. By mutual agreement, Sjoerd will remain with the Company through August 1, 2026, to ensure a smooth transition of responsibilities.

Chris Fair, Chief Executive Officer of Kuros, said: “We sincerely thank Sjoerd for his pivotal role in building and strengthening Kuros’ operational foundation during this period of rapid growth. On behalf of the entire company, I appreciate his outstanding service and wish him continued success in his future endeavors.”

“As we enter our next stage of growth with a clear focus on translating scale into operational leverage, we are committed to building the organizational depth, infrastructure and product development capabilities required to deliver on our ambitious strategic plan. I.V. brings a rare combination of building and leading high-performing R&D-driven and operationally rigorous organizations, which is exactly what Kuros needs at this stage.”

𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲 𝗮𝗯𝗼𝘂𝘁 𝘁𝗵𝗲 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝗺𝗲𝗻𝘁 𝗼𝗻 𝗼𝘂𝗿 𝗺𝗲𝗱𝗶𝗮 𝗮𝗻𝗱 𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀 𝗽𝗮𝗴𝗲.

Kuros Biosciences

06/03/2026

06/01/2026

05/29/2026

05/27/2026

05/21/2026

05/19/2026

05/14/2026

05/12/2026

05/08/2026

05/07/2026

Address

Website

Alerts

Shortcuts

Share

Category